Posted by Michael Wonder on 09 Feb 2022
Nova Scotia becomes fifth Canadian province to implement a biosimilar switching program
5 February 2022 - The province is the latest jurisdiction to adopt a program that will require patients to switch away from expensive reference biologics to select biosimilars for certain conditions.
Nova Scotia has become the fifth province and sixth jurisdiction in Canada to implement a switching policy that allows for reference products to be automatically substituted with biosimilars.
